Raman Singh
Known title: DirectorCIK: 0001747589
Associated companies
Transaction History
| LQDA | ▲ Buy | Option Exercise | 8,468 | $79K | 9/14/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 8,468 | $560K | 9/14/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 556 | $5K | 9/11/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 8,468 | $79K | 9/11/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 9,024 | $619K | 9/11/2026 | View on chart |
| LQDA | ▲ Buy | Grant | 5,882 | $0 | 6/16/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 29,494 | $1.8M | 5/21/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 19,444 | $168K | 5/21/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 10,050 | $111K | 5/21/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 20,000 | $97K | 3/13/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 20,000 | $721K | 3/13/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 25,524 | $64K | 9/15/2025 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 20,000 | $52K | 9/15/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 45,524 | $1.2M | 9/15/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 7,500 | $221K | 9/3/2025 | View on chart |
| LQDA | ▲ Buy | Grant | 18,396 | $0 | 6/17/2025 | View on chart |
| LQDA | ▲ Buy | Grant | 20,359 | $0 | 6/20/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Liquidia shares fall on patent court loss and analyst downgrades
Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.
Liquidia shares fall on patent court loss and analyst downgrades. Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.